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Abstract 
Background: This study aims to evaluate the efficacy of Xiaoyaosan (XYS) for treatment of major depressive disorder 
(MDD) and to review the studies on antidepressant mechanisms of XYS.
Methods: The China Knowledge Resource Integrated Database (1998–2014), VIP Journal Integration Platform (1989–
2009), and PubMed (1950–2014) were used to search for and collect scientific publications related to XYS and MDD. 
Clinical trials for “MDD” and “xiaoyao” were screened. Papers that used the original prescription of XYS for treatment 
and in combination with Western medicines were included, while papers describing modified XYS were excluded. 
Four investigators read and screened the resulting publications independently, evaluated the associated scientific 
results and evidence.
Results: There were no conclusive results to support the efficacy of XYS for treatment of MDD, owing to limited 
sample sizes, flaws in blinding and randomization, and lack of multi‑centered clinical trials. Among the experimental 
studies on the effects of XYS possible involvement of 5‑hydroxytryptamine, hypothalamic–pituitary–adrenal axis func‑
tion, and neuroinflammation were possibly involved demonstrated.
Conclusions: The effectiveness of XYS for treatment of MDD is uncertain.
© 2015 Jing et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Major depressive disorder (MDD) affects ~16% of the 
world population [1]. In China, the MDD prevalence 
is 9% in the general population, and 15–30% of all ado-
lescents are estimated to be affected by the disease [2]. 
Observations from 245,404 subjects in 60 countries 
revealed that the 1-year prevalence of ICD-10 depres-
sive episodes alone is 3.2% [3]. The depression comor-
bidity rate of participants with one or more chronic 
physical diseases ranges from 9.3 to 23.0% [3]. Common 
antidepressants include selective serotonin (5-hydroxy-
tryptamine; 5-HT) reuptake inhibitors (SSRIs) and sero-
tonin and norepinephrine reuptake inhibitors. The slow 
onset of action and limited efficacy of these antidepres-
sants have limited their use and prompted the search for 
novel strategies or alternative methods to combat the ill-
ness [4].
Xiaoyaosan (XYS) is a Chinese medicinal formula that 
comprises Radix Bupleuri, Radix Angelicae Sinensis, 
Radix Paeoniae Alba, Rhizoma Atractylodis Macroceph-
alae, Poria, Rhizoma Zingiberis Recens, Herba Menthae, 
and Radix Glycyrrhizae. XYS alone or combined with 
antidepressants has been used to treat MDD in China. 
However, the action mechanisms of XYS on MDD are 
still unknown.
This study aims to evaluate the efficacy of Xiaoyaosan 
(XYS) for treatment of major depressive disorder (MDD) 
and to review the studies on antidepressant mechanisms 
of XYS.
Search strategies
Literature searches were performed with the terms 
“depression” and “xiaoyao” in the China Knowledge 
Resource Integrated Database (1998–2014), VIP Jour-
nal Integration Platform (1989–2009), and PubMed 
(1950–2014). After reports describing basic research 
were excluded, a total of 110 papers on clinical trials were 
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assessed for eligibility. Papers about modified XYS were 
eliminated from the analysis, because of the difficulty 
in comparing the efficacies of medicinal formulas based 
on the incommensurability of the reports [5]. Reports 
on depression comorbidities, such as postpartum, post-
stroke, and post-cancer depression, were also excluded. 
Papers that used the original prescription of XYS for 
treatment and/or in combination with Western medi-
cines were included. A total of 15 reports on unmodified 
XYS and MDD met the inclusion criteria and were evalu-
ated in the present study (Figure 1).
Records of basic research were excluded according to 
the standard of meta-analysis of evidence-based medi-
cine. The full texts on modified XYS were eliminated 
for the incommensurability of the reports and papers 
on depression comorbidities were also excluded for our 
focus on MDD.
Efficacy of XYS
Efficacy of XYS in ameliorating MDD
Regarding the efficacy of XYS in ameliorating MDD, the 
disease showed significant improvement according to the 
traditional Chinese medicine curative index [6]. XYS also 
significantly decreased the Hamilton depression scores in 
MDD patients [7]. Controlled, randomized, and double-
blinded trials showed that the total effective rate of XYS 
in treating MDD was 91.38% in 58 patients, being sig-
nificantly higher than the value of 32.69% for the placebo 
in 52 patients [8]. XYS treatment was associated with a 
significantly decreased depression inventory score [8] 
(Table 1).
Analysis of XYS‑induced efficacy of antidepressants
The total effective rate of XYS–antidepressant combi-
nations in 12 trials was not significantly improved com-
pared with those of other antidepressants in seven trials. 
However, the cure rate was increased in one of the seven 
trials. The five remaining trials exhibited improved effec-
tive rates in the combination groups. Nine trials demon-
strated that XYS reduced side effects, four trials revealed 
decreased relapse rates, and four trials showed delays in 
onset time (Table 2).
XYS exhibited fewer side effects than antidepressants, 
but similar effectiveness. The combinations of XYS and 
antidepressants advanced the onset time and reduced 
adverse side effects in most of the trials. The methodolog-
ical quality of most included trials was generally “poor”. 
So, defects in sample sizes, blindness, and randomization 
were observed in most of the trials evaluated. Therefore, 
biases including performance and detection biases could 
not be ignored [21] (Table 3).
Mechanism of XYS as an integrated model
Hypotheses for MDD and functions of XYS
5-HT deficiency was the prevailing hypothesis for MDD 
[22, 23]. SSRIs were widely used, and accounted for about 
60–80% of the total market share of antidepressants [24]. 
XYS upregulated the 5-HT contents in the cerebral cor-
tex of a chronic restraint stress (CRS)-induced rat depres-
sion model [25], and increased the 5-HT contents in the 
hippocampus of rats with postpartum depression [26]. 
XYS could be a regulator of monoamine neurotransmit-
ters [27].
The hypothalamic–pituitary–adrenal (HPA) axis is 
governed by secretion of corticotropin-releasing hor-
mone (CRH) from the hypothalamus to activate secre-
tion of adrenocorticotropic hormone (ACTH) from the 
pituitary gland. Corticoids (cortisol in humans and cor-
ticosterone in rodents) are stimulated from the adrenal 
cortex and interact with their receptors, such as gluco-
corticoid receptors, for negative feedback control [28]. 
HPA hyperactivity results from deficits in the negative 
feedback regulation of the axis based on the failure of 
glucocorticoid receptor activation to decrease plasma 
levels of cortisol [29]. XYS downregulated CRH-1 and 
upregulated CRH-2 expression in the hypothalamus of a 
CRS-induced depressive rat model [30]. XYS decreased 
the expression of CRH-1 mRNA in paraventricular nuclei 
and increased GR expression in the hippocampus of a 
chronic unpredictable mild stress-induced depressive 
rat model [31]. Therefore, homeostasis of CRH receptors 
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Figure 1 Flow sheet summarizing the study search and selection. 
Records of basic research were excluded according to the standard of 
meta‑analysis of evidence‑based medicine. The full texts on modified 
XYS were eliminated for the incommensurability of the reports and 
papers on depression comorbidities were also excluded for our focus 
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VIP Journal Integration Platform.
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might be involved in improvement of the disequilibrium 
in the HPA system.
HPA hyperactivity was observed in 30–50% of all 
acutely depressed patients [32]. Mitochondrial dysfunc-
tions affected important functions in MDD pathogen-
esis [23]. Small deletions of mitochondrial DNA were 
observed in muscles from patients with MDD [33]. Alter-
ations in nuclear DNA-encoded mitochondrial mRNA 
and proteins in the cerebellum of MDD patients were 
also reported [34]. MDD patients with serious somatic 
complaints exhibited low ATP production rates in biop-
sied muscles [35]. These studies provide concrete evi-
dence for the clinical relevance of an association between 
low ATP supply arising through mitochondrial dysfunc-
tion and MDD. XYS was reported by our group to ame-
liorate depressive-like behaviors in rats by regulating 
mammalian target of rapamycin (mTOR), suggesting that 
XYS may exert its anti-depressive effects through regula-
tion of energy metabolism [36].
Inflammatory pathways were suggested to be involved 
in the pathophysiology of MDD through increased blood 
and cerebrospinal fluid concentrations of pro-inflamma-
tory cytokines as well as acute phase proteins and their 
receptors [37]. Cytokines interact with mitochondria to 
increase the production of reactive oxygen species (ROS). 
Increased expressions of pro-inflammatory mediators, 
neurotoxic factors, and ROS contributed to the develop-
ment of MDD [23]. XYS has been widely used for treating 
inflammatory diseases and depression comorbidities in 
hepatitis [38]. Recently, we found that XYS significantly 
reduced the serum levels of tumor necrosis factor-α 
and interleukin-6 in rats with depressive-like behaviors 
induced by chronic unpredictable mild stress (unpub-
lished data). MDD was associated with neuronal atrophy 
and neuronal cell loss, especially in the hippocampus 
and cerebral cortex [39]. Decreased brain-derived neu-
rotrophic factor (BDNF) was strongly associated with 
an increased risk for MDD [40]. A clinical meta-analysis 
showed that BDNF levels were associated with changes 
in depression [41]. BDNF was downregulated in the hip-
pocampus of a CRS-induced rat depression model [42]. 
Reports from our group and others indicated that XYS 
increased BDNF expression in the hippocampus [36, 42, 
43]. These results suggest that XYS improves MDD by 
upregulating BDNF in specific encephalic regions.
Epigenetic alterations were found in the frontal cortex 
of suicide victims with depression [44]. Antidepressants 
exerted some of their effects by causing epigenetic altera-
tions [45]. Observed dysfunctions of biological clocks 
were related to MDD [46]. Patients with depression often 
showed altered circadian rhythms, sleep disturbances, 
and variations in diurnal moods [47]. The degree of cir-
cadian misalignment was correlated with the severity of 
depressive symptoms [47]. The actions of XYS on epige-
netic modifications and circadian rhythms are significant, 
because this medicinal formula is efficacious in the treat-
ment of sleeping and mood disorders.
Integrated hypothesis for MDD as a unified mechanism 
of XYS
Hypotheses for MDD include 5-HT depletion, neurotro-
phin deficiency, neuroinflammation, mitochondrial dys-
function, HPA hyperactivity, epigenetic variation, and 
circadian dysrhythmia. However, the pathophysiology of 
MDD has rarely been studied and the published hypoth-
eses are far from mutually exclusive.
The theory of inadequate monoamine neurotrans-
mission, in which antidepressants increase monoamine 
availability and produce long-term adaptive changes in 
monoaminergic receptor sensitivity [48], is insufficient 
to explain MDD. Lowered plasma tryptophan reduced 
5-HT synthesis and aggravated MDD symptoms [49]. 
N-acetylserotonin, an intermediate product of mela-
tonin formation from 5-HT, is a specific agonist of BDNF 
receptors, and 5-HT is a substrate for melatonin biosyn-
thesis. Melatonin deficiency contributed to primary and 
Table 1 Summary of published clinical trials on XYS in the treatment of MDD
CCMD China classification and diagnostic criteria for mental disorder, HAMD Hamilton depression scale, CGI clinical global impression, N/A not available, ↑ significant 
increase compared with control, ↓ significant decrease compared with control.



















Xian et al. [6] 60 CCMD‑3 XYS  
decoction
Fluoxetine Random  
number 
table
Single 6 N/A N/A ↑ ↓ N/A N/A
Zhang et al. [8] 110 Depression 
Inventory 
(DI)
Xiaoyao pill Placebo Random  
number 
table
Double 8 N/A N/A ↑ (DI) N/A N/A N/A
Feng et al. [7] 58 CCMD‑3 XYS  
decoction
N/A N/A N/A 8 N/A ↑ ↑(CGI) N/A N/A N/A
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depression-associated insomnia as well as disturbances 
in circadian rhythms [50].
Neuroinflammation, which is characterized by 
increased production of interferon-γ, interleukin-6, and 
tumor necrosis factor-α, and induction of indoleamine 
2,3-dioxygenase (IDO) in the blood and brain, plays a 
role in depression [37]. Activation of IDO reduces plasma 
tryptophan and brain 5-HT and increases the levels of 
tryptophan catabolites (TRYCATs), such as quinolinic 
and picolinic acids. Inflammation increases CRH and 
ACTH secretion. Cortisol levels are increased to acti-
vate liver tryptophan 2,3-dioxygenase, which further 
decreases plasma tryptophan and increases TRYCAT 
production. TRYCATs generate ROS, cause mitochon-
drial dysfunctions, and interfere with energy metabolism. 
They also potently activate NMDA receptors and induce 
pro-inflammatory responses and neuron apoptosis. 
These findings imply a shift from tryptophan and 5-HT 
depletion toward the detrimental effects of TRYCATs. 
IDO links the neuroinflammation and neurotoxicity of 
TRYCATs, which jointly promote the development of 
depressive symptoms [49].
Psychosocial stresses arising from life events can 
potentially induce continuous increases in stress hor-
mones, which impair negative-feedback mechanisms 
and lead to continuous hyperactivity of the HPA axis. 
Pro-inflammatory cytokines are also potential activa-
tors of the HPA axis, thereby increasing the secretion 
of glucocorticoids, which are markers of glucocorticoid 
resistance. Glucocorticoids augment the alternative 
pathway for IDO-catalyzed tryptophan and decrease the 
amount of 5-HT available in synapses by increasing the 
expression of the serotonin transporter gene. Prolonged 
increases in glucocorticoids desensitize their recep-
tors on immune cells, such as macrophages. Activation 
of macrophages in the periphery and brain occurred 
and pro-inflammatory cytokines were released in MDD 
patients [37]. Psychosocial stresses decrease the levels 
of BDNF and other neurotrophic/growth factors, while 
increasing the glucocorticoid concentration. Multiple 
interaction pathways exist between pro-inflammatory 
immune functions, brain and neuronal structures, brain 
serotonergic systems, and the HPA axis. The HPA axis is 
a key integrative component that links primary biological 
and psychosocial theories [36].
Dysfunction of the hippocampus, cerebellum, insula, 
frontal cortex, and temporal cortex could eventually 
contribute to the pathogenesis of MDD. The integrated 
model conjectures a general-purpose co-processor, 
whose effects depend on the specific brain centers to 
which individual modules are connected [51]. The dis-
parate modules and different ideas on MDD emphasize 
the internal relationships among the different hypotheses 
(Figure 2).
Future directions and implications
Although XYS is a widely used medicinal formula in 
China, the research results are not commensurable 
among the various modifications of XYS, i.e., different 
ingredients because of their origins, and forms of pre-
scriptions, such as powders, decoctions, and pills. A new 
strategy for Chinese medicine quality control called for-
mulomics was proposed to analyze XYS [52]. This strat-
egy emphasizes strict extract quality control for XYS by 
Table 3 Quality assessment of included trials











Xian et al. [6] Yes Yes No Yes Unclear No
Feng et al. [7] Yes Yes Yes Yes Unclear No
Zhang et al. [8] Unclear Unclear No Unclear Unclear No
Wang et al. [9] Unclear Unclear No Unclear Unclear Yes
Wang et al. [10] Unclear Unclear No Unclear Unclear No
Nan et al. [11] Unclear Unclear No Unclear Unclear No
Li et al. [12] Unclear Unclear Yes Unclear Unclear No
Du et al. [13] Unclear Unclear Yes Unclear Unclear Yes
Ma [14] Yes Unclear Yes Unclear Unclear No
Chen [15] Unclear Unclear No Unclear Unclear No
Zhai et al. [16] Unclear Unclear No Unclear Unclear No
Zhang et al. [17] Unclear Unclear No Unclear Unclear No
Zhang et al. [18] Unclear Unclear Yes Unclear Unclear No
Xia et al. [19] Unclear Unclear No Unclear Unclear No
Xiang [20] Unclear Unclear No Unclear Unclear No
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liquid chromatography/mass spectrometry for chemi-
cal characterization and chemical fingerprinting [53], 
and recommends a fixed material origin and basis, and 
a standard extraction protocol. Targets for XYS in MDD 
must be screened with omics approaches and repeatedly 
confirmed using transgenic knockdown or knockin mice.
Conclusions
The effectiveness of XYS for treatment of MDD is 
uncertain.
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